- Raw materials
- Antipsychotics
- Mosapramine
Mosapramine API Manufacturers & Suppliers
0 verified results
All Mosapramine data. Full access. Full negotiation power
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Mosapramine | CAS No: 89419-40-9 | GMP-certified suppliers
A medication that serves as an investigational antipsychotic agent targeting central nervous system disorders with potential benefits in managing psychotic symptoms.
Therapeutic categories
Product Snapshot
- Mosapramine is an oral small molecule antipsychotic agent
- It is primarily investigated for the treatment of psychiatric disorders such as schizophrenia
- The compound remains in experimental status with no current FDA or EMA approval
Clinical Overview
Mosapramine is currently designated as an experimental compound with investigational status and is included in drug categories such as antipsychotic agents, CNS depressants, and psycholeptics. It is also noted among heterocyclic fused-ring compounds with neuroactive properties, including potential neurotoxicity as suggested by its classification. However, specific clinical indications, pharmacodynamics, and mechanistic data remain undisclosed in public pharmacopeia and regulatory documentation.
The mechanism of action of mosapramine has not been explicitly elucidated but, consistent with dibenzazepine antipsychotics, it may involve modulation of dopaminergic and serotonergic neurotransmitter pathways. Typically, agents in this chemical and therapeutic class act by antagonizing dopamine D2 receptors, contributing to antipsychotic activity, although confirmatory data are not available for mosapramine.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for mosapramine have not been reported. Given its molecular framework, customary metabolic pathways may involve hepatic biotransformation via cytochrome P450 enzymes with subsequent renal and fecal elimination; nonetheless, specific pharmacokinetic profiles require formal characterization.
Safety and toxicity assessments for mosapramine are limited, reflecting its status as an experimental molecule. Potential neurotoxicity and CNS depressant effects warrant cautious evaluation during any preclinical or clinical investigation phases.
As an investigational API, sourcing of mosapramine should prioritize manufacturers complying with current Good Manufacturing Practices (cGMP) and capable of providing comprehensive quality documentation. Purity, polymorphic form, and impurity profiles must be stringently controlled to support regulatory submissions and ensure reproducible pharmacological activity in downstream formulation development.
Identification & chemistry
| Generic name | Mosapramine |
|---|---|
| Molecule type | Small molecule |
| CAS | 89419-40-9 |
| UNII | 04UZQ7O9SJ |
| DrugBank ID | DB13676 |
Formulation & handling
- Mosapramine is a lipophilic small molecule with low aqueous solubility, favoring formulations for oral administration.
- The compound’s dibenzazepine structure suggests moderate stability under standard storage but warrants protection from oxidative conditions.
- Due to its physicochemical properties, formulation strategies should consider enhancing solubility and bioavailability.
Regulatory status
Mosapramine is a type of Antipsychotics
Antipsychotics belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category used to treat psychiatric disorders such as schizophrenia, bipolar disorder, and other related conditions. These medications play a crucial role in managing symptoms associated with psychosis, including hallucinations, delusions, and disorganized thinking.
Antipsychotics work by modulating the levels of neurotransmitters in the brain, particularly dopamine and serotonin. They can be categorized into two classes: first-generation (typical) antipsychotics and second-generation (atypical) antipsychotics. Typical antipsychotics primarily target dopamine receptors, while atypical antipsychotics also affect serotonin receptors.
The pharmaceutical API category of antipsychotics includes various well-known drugs, such as haloperidol, chlorpromazine, risperidone, quetiapine, and olanzapine. These APIs are often formulated into different dosage forms, including tablets, capsules, injections, and oral suspensions, to provide flexibility in administration and patient-specific needs.
Antipsychotics offer relief from psychotic symptoms by stabilizing the imbalanced neurotransmitter activity in the brain. However, they may also have certain side effects, such as sedation, weight gain, extrapyramidal symptoms, and metabolic disturbances. It is essential for healthcare professionals to carefully monitor patients receiving antipsychotic treatment to optimize therapeutic benefits while minimizing adverse effects.
In summary, antipsychotics are a vital category of pharmaceutical APIs used to manage psychiatric disorders by modulating neurotransmitter activity in the brain. Their effectiveness in treating psychosis has made them a cornerstone of mental health treatment, providing much-needed relief to individuals suffering from these conditions.
